Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications

International Journal of Bipolar Disorders

Volumn 4, Issue 1, 2016, Pages

  Charles, Ellen F ^a   Lambert, Christophe G ^b   Kerner, Berit ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Bipolar disorder; Cohort studies; Diabetes; Epidemiology; Evidence; Pathophysiology

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; HEMOGLOBIN A1C; NORADRENALIN;

AGE; ALCOHOL CONSUMPTION; ANXIETY DISORDER; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HYPERLIPIDEMIA; MENTAL HEALTH; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 85020429463     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/s40345-016-0054-4     Document Type: Review

References (121)

1. Alvarez Ariza M. Mateos Alvarez R, Berrios GE. A review of the natural course of bipolar disorders (manic-depressive psychosis) in the pre-drug era: review of studies prior to 1950. J Affect Disord. 2009;115:293–301.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.
3. Bai YM, Su TP, Chen MH, Chen TJ, Chang WH. Risk of developing diabetes mellitus and hyperlipidemia among patients with bipolar disorder, major depressive disorder, and schizophrenia: a 10-year nationwide population-based prospective cohort study. J Affect Disord. 2013;150:57–62.
4. Bajor LA, Gunzler D, Einstadter D, Thomas C, McCormick R, Perzynski AT, et al. Associations between comorbid anxiety, diabetes control, and overall medical burden in patients with serious mental illness and diabetes. Int J Psychiatry Med. 2015;49:309–20.
5. Bauer M, Glenn T, Pilhatsch M, Pfennig A, Whybrow PC. Gender differences in thyroid system function: relevance to bipolar disorder and its treatment. Bipolar Disord. 2014;16:58–71.
6. Beers E, Moerkerken DC, Leufkens HG, Egberts TC, Jansen PA. Participation of older people in preauthorization trials of recently approved medicines. J Am Geriatr Soc. 2014;62:1883–90.
7. Bellivier F, Golmard JL, Henry C, Leboyer M, Schürhoff F. Admixture analysis of age at onset in bipolar I affective disorder. Arch Gen Psychiatry. 2001;58:510–2.
8. Bellivier F, Golmard JL, Rietschel M, Schulze TG, Malafosse A, Preisig M, et al. Age at onset in bipolar I affective disorder: further evidence for three subgroups. Am J Psychiatry. 2003;160:999–1001.
9. Biessels GJ, Reijmer YD. Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetes. 2014;63:2244–52.
10. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64–74.
11. Calkin CV, Gardner DM, Ransom T, Alda M. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann Med. 2013;45:171–81.
12. Calkin CV, Ruzickova M, Uher R, Hajek T, Slaney CM, Garnham JS, et al. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry. 2015;206:52–7.
13. Callaghan RC, Khizar A. The incidence of cardiovascular morbidity among patients with bipolar disorder: a population-based longitudinal study in Ontario, Canada. J Affect Disord. 2010;122:118–23.
14. Carliner H, Collins PY, Cabassa LJ, McNallen A, Joestl SS, Lewis-Fernández R. Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review. Compr Psychiatry. 2014;55:233–47.
15. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417–20.
16. Center for Disease Control. National diabetes statistics report. 2014. http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html. Accessed 30 July 2015.
17. Chang YC, Chuang LM. The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Trans Res. 2010;2:316–31.
18. Chen MH, Li CT, Lin WC, Wei HT, Chang WH, Chen TJ, et al. A predisposition for allergies predicts subsequent hypertension, dyslipidemia, and diabetes mellitus among patients with schizophrenia or bipolar disorder: a nationwide longitudinal study. Schizoph Res. 2014;159:171–5.
19. Chien IC, Chang KC, Lin CH, Chou YJ, Chou P. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry. 2010;32:577–82.
20. Choi JH, Choi SS, Kim ES, Jedrychowski MP, Yang YR, Jang HJ, et al. Thrap3 docks on phosphoserine 273 of PPARγ and controls diabetic gene programming. Genes Dev. 2014;28:2361–9.
21. Chwastiak LA, Davydow DS, McKibbin CL, Schur E, Burley M, McDonell MG, et al. The effect of serious mental illness on the risk of rehospitalization among patients with diabetes. Psychosomatics. 2014;55:134–43.
22. Conn VS, Koopman RJ, Ruppar TM, Phillips LJ, Mehr DR, Hafdahl AR. Insulin sensitivity following exercise interventions: systematic review and meta-analysis of outcomes among healthy adults. J Prim Care Commun Health. 2014;5:211–22.
23. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119–36.
24. Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70:931–9.
25. Datusalia AK, Sharma SS. Amelioration of diabetes-induced cognitive deficits by GSK-3β inhibition is attributed to modulation of neurotransmitters and neuroinflammation. Mol Neurobiol. 2014;50:390–405.
26. Davydow DS, Ribe AR, Pedersen HS, Fenger-Grøn M, Cerimele JM, Vedsted P, et al. Serious mental illness and risk for hospitalizations and rehospitalizations for ambulatory care-sensitive conditions in Denmark: a nationwide population-based cohort study. Med Care. 2015;21:90.
27. De Bresser J, Tiehuis AM, van den Berg E, Reijmer YD, Jongen C, Kappelle LJ, et al. Progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes. Diabetes Care. 2010;33:1309–14.
28. Delaloye C, Moy G, De Bilbao F, Weber K, Baudois S, Haller S, et al. Longitudinal analysis of cognitive performances and structural brain changes in late-life bipolar disorder. Int J Geriat Psychiatry. 2011;26:1309–18.
29. Depp CA, Jeste DV. Bipolar disorder in older adults: a critical review. Bipolar Disord. 2004;6:343–67.
30. Depp CA, Strassnig M, Mausbach BT, Bowie CR, Wolyniec P, Thornquist MH, et al. Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. Bipolar Disord. 2014;16:422–31.
31. Dols A, Kupka RW, van Lammeren A, Beekman AT, Sajatovic M, Stek ML. The prevalence of late-life mania: a review. Bipolar Disord. 2014;16:113–8.
32. Esquirol JED. Mental maladies, a treatise on insanity. Philadelphia: Lea and Blanchard; 1845. p. 1845.
33. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the bipolar disorder center for Pennsylvanians. Bipolar Disord. 2005;7:424–30.
34. Fitzgerald PJ. Noradrenaline transmission reducing drugs may protect against a broad range of diseases. Auton Autacoid Pharmacol. 2015;34:15–26.
35. Fleet-Michaliszyn SB, Soreca I, Otto AD, Jakicic JM, Fagiolini A, Kupfer DJ, et al. A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects. J Clin Psychiatry. 2008;69:1892–900.
36. Foley DL, Mackinnon A, Morgan VA, Watts GF, Castle DJ, Waterreus A, et al. Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study. Lancet Psychiatry. 2015;2:1092–8.
37. García-Casares N, Berthier ML, Jorge RE, Gonzalez-Alegre P, Gutiérrez Cardo A, Rioja Villodres J, et al. Structural and functional brain changes in middle-aged type 2 diabetic patients: a cross-sectional study. J Alzheimers Dis. 2014;40:375–86.
38. García-Rizo C, Kirkpatrick B, Fernandez-Egea E, Oliveira C, Meseguer A, Grande I, et al. “Is bipolar disorder an endocrine condition?” Glucose abnormalities in bipolar disorder. Acta Psychiatr Scand. 2014;129:73–4.
39. Gierisch JM, Beadles C, Shapiro A, McDuffie JR, Cunningham N, Bradford D, et al. Health disparities in quality indicators of healthcare. Department of Veterans Affairs (US): Washington (DC); 2014.
40. Goldstein BI, Kemp DE, Soczynska JK, Mcintyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70:1078–90.
41. Goldstein BI, Liu SM, Zivkovic N, Schaffer A, Chien LC, Blanco C. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011;13:387–95.
42. Gomes FA, Almeida KM, Magalhães PV, Caetano SC, Kauer-Sant’Anna M, Lafer B, et al. Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian research network in bipolar disorder. Rev Bras Psiquiatr. 2013;35:126–30.
43. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology. 2004;29:32–8.
44. Guha P, Bhowmick K, Mazumder P, Ghosal M, Chakraborty I, Burman P. Assessment of insulin resistance and metabolic syndrome in drug naive patients of bipolar disorder. Indian J Clin Biochem. 2014;29:51–6.
45. Hajek T, Calkin C, Blagdon R, Slaney C, Alda M. Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol Psychiatry. 2015;77:295–303.
46. Hajek T, Calkin C, Blagdon R, Slaney C, Uher R, Alda M. Insulin resistance, diabetes mellitus, and brain structure in bipolar disorders. Neuropsychopharmacology. 2014;39:2910–8.
47. Hamdani N, Doukhan R, Kurtlucan O, Tamouza R, Leboyer M. Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications. Curr Psychiatry Rep. 2013;15:387.
48. Hendrie HC, Lindgren D, Hay DP, Lane KA, Gao S, Purnell C, et al. Comorbidity profile and healthcare utilization in elderly patients with serious mental illnesses. Am J Geriatr Psychiatry. 2013;21:1267–76.
49. Hsieh MH, Tang CH, Hsieh MH, Lee IH, Lai TJ, Lin YJ, et al. Medical costs and vasculometabolic comorbidities among patients with bipolar disorder in Taiwan a population-based and matched-control study. J Affect Disord. 2012;141:449–56.
50. Huang S, Zhu M, Wu W, Rashid A, Liang Y, Hou L, et al. Valproate pretreatment protects pancreatic β-cells from palmitate-induced ER stress and apoptosis by inhibiting glycogen synthase kinase-3β. J Biomed Sci. 2014;21:38.
51. Iwahashi K, Nishizawa D, Narita S, Numajiri M, Murayama O, Yoshihara E, et al. Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders. Clin Neuropharmacol. 2014;37:108–10.
52. Iwen KA, Schröder E, Brabant G. Thyroid hormones and the metabolic syndrome. Eur Thyroid J. 2013;2:83–92.
53. Jann MW. Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. Am Health Drug Benefits. 2014;7:489–99.
54. Janney CA, Fagiolini A, Swartz HA, Jakicic JM, Holleman RG, Richardson CR. Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry. J Affect Disord. 2014;152–154:498–504.
55. Janssen EM, McGinty EE, Azrin ST, Juliano-Bult D, Daumit GL. Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. Gen Hosp Psychiatry. 2015;37:199–222.
56. Kennedy N, Everitt B, Boydell J, Van Os J, Jones PB, Murray RM. Incidence and distribution of first-episode mania by age: results from a 35-year study. Psychol Med. 2005;35:855–63.
57. Kim HK, Chen W, Andreazza AC. The potential role of the NLRP3 inflammasome as a link between mitochondrial complex I dysfunction and inflammation in bipolar disorder. Neural Plast. 2015;2015:408136.
58. King MR, Anderson NJ, Guernsey LS, Jolivalt CG. Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice. J Neurosci Res. 2013;91:506–14.
59. Kodesh A, Goldshtein I, Gelkopf M, Goren I, Chodick G, Shalev V. Epidemiology and comorbidity of severe mental illnesses in the community: findings from a computerized mental health registry in a large Israeli health organization. Soc Psychiatry Psychiatr Epidemiol. 2012;47:1775–82.
60. Konz HW, Meesters PD, Paans NP, van Grootheest DS, Comijs HC, Stek ML, et al. Screening for metabolic syndrome in older patients with severe mental illness. Am J Geriat Psychiatry. 2014;22:1116–20.
61. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20.
62. Ladefoged M, Buschard K, Hansen AM. Increased expression of toll-like receptor 4 and inflammatory cytokines, interleukin-6 in particular, in islets from a mouse model of obesity and type 2 diabetes. APMIS. 2013;121:531–8.
63. Lala SV, Sajatovic M. Medical and psychiatric comorbidities among elderly individuals with bipolar disorder: a literature review. J Geriatr Psychiatry Neurol. 2012;25:20–5.
64. Leboyer M, Henry C, Paillere-Martinot ML, Bellivier F. Age at onset in bipolar affective disorders: a review. Bipolar Disord. 2005;7:111–8.
65. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 2012;141:1–10.
66. Li J, Sun X, Yu Y. The prevalence of impaired glucose regulation in psychiatric patients with sleep disorders and its relationship with altered hypothalamopituitary–adrenal and hypothalamopituitary–thyroid axis activity. Sleep Med. 2013;14:662–7.
67. Lilliker SL. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry. 1980;21:270–5.
68. Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol. 2013;48:190–204.
69. Maina G, Bechon E, Rigardetto S, Salvi V. General medical conditions are associated with delay to treatment in patients with bipolar disorder. Psychosomatics. 2013;54:437–42.
70. Maina G, Salvi V, Vitalucci A, D’ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. J Affect Disord. 2008;110:149–55.
71. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65:634–51.
72. McGinty EE, Baller J, Azrin ST, Juliano-Bult D, Daumit GL. Quality of medical care for persons with serious mental illness: a comprehensive review. Schizophr Res. 2015;165:227–35.
73. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17:83–93.
74. McKernan DP, Dennison U, Gaszner G, Cryan JF, Dinan TG. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Transl Psychiatry. 2011;1:e36.
75. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry. 2007;64:543–52.
76. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241–51.
77. Perseghin G, Price TB, Petersen KF, Roden M, Cline GW, Gerow K, et al. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med. 1996;335:1357–62.
78. Perugi G, Quaranta G, Belletti S, Casalini F, Mosti N, Toni C, et al. General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune–allergic diseases. J Affect Disord. 2015;170:95–103.
79. Préville M, Boyer R, Grenier S, Dubé M, Voyer P, Punti R, et al. The epidemiology of psychiatric disorders in Quebec’s older adult population. Can J Psychiatry. 2008;53:822–32.
80. Préville M, Boyer R, Vasiliadis HM, Grenier S, Voyer P, Hudon C, et al. One-year incidence of psychiatric disorders in Quebec’s older adult population. Can J Psychiatry. 2010;55:449–57.
81. Qu ZS, Li L, Sun XJ, Zhao YW, Zhang J, Geng Z, et al. Glycogen synthase kinase-3 regulates production of amyloid-β peptides and tau phosphorylation in diabetic rat brain. Sci World J. 2014;2014:878123.
82. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord. 2002;70:19–26.
83. Reijmer YD, van den Berg E, de Bresser J, Kessels RP, Kappelle LJ, Algra A, et al. Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors. Diabetes/Metab Res Rev. 2011;27:195–202.
84. Reininghaus EZ, Zelzer S, Reininghaus B, Lackner N, Birner A, Bengesser SA, et al. Oxidativer Stress bei bipolar affektiver Störung [Oxidative stress in bipolar affective disorder]. Nervenarzt. 2014;85:1099–107.
85. Rennie T. Prognosis in manic-depressive psychoses. Am J Psychiatry. 1942;98:801–14.
86. Ronai Z, Kovacs-Nagy R, Szantai E, Elek Z, Sasvari-Szekely M, Faludi G, et al. Glycogen synthase kinase 3 beta gene structural variants as possible risk factors of bipolar depression. Am J Med Gen B Neuropsychiatr Genet. 2014;165B:217–22.
87. Rosenblat JD, McIntyre RS. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? Acta Psychiatr Scand. 2015;132:180–91.
88. Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry. 2003;48:458–61.
89. Sajatovic M, Blow FC, Ignacio RV, Kales HC. New-onset bipolar disorder in later life. Am J Geriatr Psychiatry. 2005;13:282–9.
90. Sajatovic M, Chen P. Geriatric bipolar disorder. Psychiatr Clin North Am. 2011;34:319–33.
91. Sajatovic M, Strejilevich SA, Gildengers AG, Dols A, Al Jurdi RK, Forester BP, et al. A report on older-age bipolar disorder from the international society for bipolar disorders task force. Bipolar Disord. 2015a;17:689–704.
92. Sajatovic M, Gunzler D, Einstadter D, Thomas C, McCormick RA, Perzynski AT, et al. Clinical characteristics of individuals with serious mental illness and type 2 diabetes. Psychiatr Serv. 2015b;66:197–9.
93. Salvadore G, Viale CI, Luckenbaugh DA, Zanatto VC, Portela LV, Souza DO, et al. Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:819–21.
94. Sami M, Khan H, Nilforooshan R. Late onset mania as an organic syndrome: a review of case reports in the literature. J Affect Disord. 2015;188:226–31.
95. Schoepf D, Heun R. Bipolar disorder and comorbidity: increased prevalence and increased relevance of comorbidity for hospital-based mortality during a 12.5-year observation period in general hospital admissions. J Affect Disord. 2014;169:170–8.
96. Schouws SN, Comijs HC, Stek ML, Dekker J, Oostervink F, Naarding P, et al. Cognitive impairment in early and late bipolar disorder. Am J Geriatr Psychiatry. 2009;17:508–15.
97. Schouws SN, Stek ML, Comijs HC, Dols A, Beekman AT. Cognitive decline in elderly bipolar disorder patients: a follow-up study. Bipolar Disord. 2012;14:749–55.
98. Sharma AN, Bauer IE, Sanches M, Galvez JF, Zunta-Soares GB, Quevedo J, et al. Common biological mechanisms between bipolar disorder and type 2 diabetes: focus on inflammation. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:289–98.
99. Sheeran T, Greenberg RL, Davan LA, Dealy JA, Young RC, Bruce ML. A descriptive study of older bipolar disorder residents living in New York City’s adult congregate facilities. Bipolar Disord. 2012;14:756–63.
100. Smith DJ, Martin D, McLean G, Langan J, Guthrie B, Mercer SW. Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study. BMC Med. 2013;11:263.
101. Stenstedt A. A study in manic-depressive psychosis; clinical, social and genetic investigations. Acta Psychiatr Neurol Scand. 1952;79:1–111.
102. Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: a nationwide population-based study with focus on gender differences. BMC Med. 2012;10:148.
103. Swift HM. The prognosis of recurrent insanity of the manic depressive type. Am J Psychiatry. 1907;64:311–26.
104. Sylvia LG, Shelton RC, Kemp DE, Bernstein EE, Friedman ES, Brody BD, et al. Medical burden in bipolar disorder: findings from the clinical and health outcomes initiative in comparative effectiveness for bipolar disorder study (bipolar choice). Bipolar Disord. 2015;17:212–23.
105. Thakurathi N, Henderson DC. Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder. Evid Based Ment Health. 2012;15:61.
106. Tsai SY, Kuo CJ, Chung KH, Huang YL, Lee HC, Chen CC. Cognitive dysfunction and medical morbidity in elderly outpatients with bipolar disorder. Am J Geriatr Psychiatry. 2009;17:1004–11.
107. Vancampfort D, Mitchell AJ, De Hert M, Sienaert P, Probst M, Buys R, et al. Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2015;76:1490–9.
108. Vasudev A, Thomas A. Bipolar disorder in the elderly: what’s in a name? Maturitas. 2010;66:231–5.
109. Vinogradova Y, Coupland C, Hippisley-cox J, Whyte S, Penny C. Effects of severe mental illness on survival of people with diabetes. Br J Psychiatry. 2010;197:272–7.
110. Volkert J, Schulz H, Härter M, Wlodarczyk O, Andreas S. The prevalence of mental disorders in older people in Western countries—a meta-analysis. Ageing Res Rev. 2013;12:339–53.
111. Wändell P, Ljunggren G, Wahlström L, Carlsson AC. Diabetes and psychiatric illness in the total population of Stockholm. J Psychosom Res. 2014;77:169–73.
112. Wang C. The relationship between type 2 diabetes mellitus and related thyroid diseases. J Diabetes Res. 2013;2013:390534.
113. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36:166–75.
114. Weston-Green K, Huang XF, Deng C. Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. CNS Drugs. 2013;27:1069–80.
115. Wisse LE, de Bresser J, Geerlings MI, Reijmer YD, Portegies ML, Brundel M, et al. Global brain atrophy but not hippocampal atrophy is related to type 2 diabetes. J Neurol Sci. 2014;344:32–6.
116. Wright E, Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract. 2006;60:308–14.
117. Wu KY, Chang CM, Liang HY, Wu CS, Chia-Hsuan WuE, Chen CH, et al. Increased risk of developing dementia in patients with bipolar disorder: a nested matched case-control study. Bipolar Disord. 2013;15:787–94.
118. Wysokiński A, Strzelecki D, Kłoszewska I. Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder. Diabetes Metab Syndr. 2015;9:168–76.
119. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes. 2009;58:71–7.
120. Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, et al. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2015;32:167–73.
121. Zilkens RR, Bruce DG, Duke J, Spilsbury K, Semmens JB. Severe psychiatric disorders in mid-life and risk of dementia in late-life (age 65–84 years): a population based case–control study. Curr Alzheimer Res. 2014;11:681–93.